Macroaxis: Personalized Investing
Simple Personalized Investing

S&P 500   1,667   17.00  Index Moved Up 1.03%
JNJ PFE NVS SNY Farming Large Blend Impulse Long-Short 
United States  USA  |  Macroaxis Daily Picks


Processing
Collecting data for LLY

Eli Lilly quote and profile

 
 Companies |  Insiders  | Dashboard  
     
55.9
  
STOCK
(0.04)  Macroaxis: -0.07 Down   0.07%  
Year To Date
39.9358.4
Trading Day 
55.3556.23
May 19 2013 

Diversification Suggestion

Use Eli Lilly to protect against small markets fluctuations. The stock experiences normal downward trend and little activity
Analyze Eli Lilly and Trend or Check current 30 days Eli Lilly correlation with market (S&P 500)
1 Month Beta 0.94  
Highest Price:  
Lowest Price:  
58.33  
54.17  
April 23 2013 
May 07 2013 
Eli Lilly returns are very sensitive to returns on the market. As market goes up or down, Eli Lilly is expected to follow.
Eli Lilly and Company llmost one BetaEli Lilly and Beta Legend
LLY United States NYSE
Eli Lilly and Company
Healthcare
Drug Manufacturers - Major
http://www.lilly.com
Contact Number: 317. 276. 2000
Currency: USD - US Dollar
Traded on New York Stock Exchange
    
Current Valuation60.14 B
Shares Outstanding1.08 B
Number of Shares Shorted14.97 M
Revenue22.6 B
 United States Russel   1.11 % Macroaxis: change 1.11 Moved Up  
 
 United States SP 500   1.03 % Macroaxis: change 1.03 Moved Up  
 
 United States Nasdaq   0.97 % Macroaxis: 0.97 Moved Up  
 
 United States NYSE   0.92 % Macroaxis: 0.92 Moved Up  
 
 thisRed LLY LLY agains markets  0.07 % Macroaxis: 0.07 Moved Down  
 
Compare to Competition Get Alpha   Get Advice

Eli Lilly Leadership

Derica Rice Acting CEO, CFO, Executive VP of Global Services, Member of Operations Committee and Member of Policy and Strategy Committee, MBA
John Lechleiter Chairman, CEO and Pres
Barton Peterson Senior Vice President - Corporate Affairs and Communications
Susan Mahony Senior Vice President and President - Lilly Oncology, MBA

Eli Lilly Price and Market Media

The median price of Eli Lilly for the period between Fri, Apr 19, 2013 and Sun, May 19, 2013 is 55.9 with a coefficient of variation of 2.09. The daily time series for the period is distributed with a sample standard deviation of 1.17, arithmetic mean of 55.75, and mean deviation of 0.95. The Stock received substential amount of media coverage during this period.
Eli Lilly         Market
Price Growth (%)
 
1
Eli Lilly and Co. earnings increase though revenues flat04/25/2013Macroaxis: News
2
Eli Lilly and Co. Given quotUnderperformquot Rating at Jeffe...05/01/2013Macroaxis: News
3
Insulet teams up with Eli Lilly to roll out new insulin pump05/03/2013Macroaxis: Bizjournals News
4
Eli Lilly and Co. chairman to undergo surgery on aorta05/07/2013Macroaxis: News
5
Eli Lilly and Company ExDividend Date Scheduled for May 14 2...05/14/2013Macroaxis: News
6
Lilly gives 1 million for art museum initiative05/16/2013Macroaxis: News

Eli Lilly Summary

Eli Lilly and Company [LLY] is traded on New York Stock Exchange in USA. It is located in Indianapolis, IN and employs 38,350 people. The company currently falls under 'Large-Cap' category with total capitalization of 60.57 B. Eli Lilly and Company runs under Healthcare sector within Drug Manufacturers - Major industry. This company has 1.08 B outstanding shares of which 14.97 M shares are now shorted by investors with about 3.3 days to cover shorted positions.
Eli Lilly and Company discovers, develops, manufactures, and sells pharmaceutical solutions worldwide. more
Past Market
Over 30
Days
0
Out Of
100
 
Chance of
Less
Than
%
 
Follow Eli Lilly with Macroaxis syndicated feed, custom widget, or your favorite custom stock ticker
Add To Reader
 
Add Eli Lilly to your reader
 

Eli Lilly Research Report

Eli Lilly vs. Johnson

Correlation analysis and fundamentals comparison between Eli Lilly and and Johnson Johnson

Eli Lilly Directors

R Hoover Independent Director
Ellen Marram Lead Independent Director
William Kaelin Director
J Fyrwald Independent Director
Katherine Baicker Independent Director

Eli Lilly Fundamentals

Debt to Equity vs Book Value Per Share
Return On Asset vs Z Score
Debt to Equity vs Price to Book
Profit Margin vs Z Score

Eli Lilly vs Competition

Eli Lilly vs. Johnson Johnson
Eli Lilly vs. Pfizer Inc
Eli Lilly vs. Novartis AG
Eli Lilly vs. Sanofi
Eli Lilly vs. Merck Co Inc
Eli Lilly vs. GlaxoSmithKline plc
Eli Lilly vs. BristolMyers Squibb Company
Eli Lilly vs. AstraZeneca PLC
Eli Lilly vs. Impax Laboratories Inc

Eli Lilly May 19 2013 Opportunity Range

Downside Deviation1.77
Information Ratio(0.33)
Maximum Drawdown5.21
Value At Risk(2.06)
Potential Upside1.52

 
Analytics
Risk Adjusted Returns Landscape
Live Efficient Frontier
Market Correlation Analysis
Watchlist Analysis
Financial Content
Portfolio Estimation and Projections
Portfolio Theme Builder
 
 
Research Modules
Equities Backtesting Analysis
Instant Retirement Optimizer
Cross-portfolio RSS and Mobile Access
Company, fund, and ETF Directory
Financial Advisor Directory
Insider and Manager Directory
Wealth Management
 Gadgets, Widgets, and Apps          
  
 
Services And Technology
Frequently Asked Questions
Quick Product Tour
Product Technology Overview
Solution Methodology
Plans and Pricing
 
Free Investor Tools
World Market Correlations
Instant Equity Comparator
Watchlist Analysis
Position Suggestions
Equity Alpha Analysis
 
About Us
About Macroaxis
Contact Us
Product Terms Of Use
Service Privacy Policy
Advertising Opportunities
Content

Thanks for checking out Macroaxis

Tell us what you like and what you don't like. We promise we'll not only listen but write you back

Contact Us
Macroaxis is user-driven community of investors. We appreciate any feedback or comment you can provide. Please fill out our quick survey to help us provide your with a better service and user experience

Fill Out Quick Survey
Most of the functionality on our site is free to use. However we do provide premium service to sophisticated investors. Our premium subscription will give you unprecedented capabilities to optimize your portfolios using robust financial analysis toolkit, fast mean-variance optimization engine, and proven portfolio theory

Go Premium